By Desiree Housek, Staff Writer Sanofi-Aventis, the manufacturer of Taxotere is currently being investigated for failing to adequately warn patients and physicians of the risk of permanent hair loss. Below is a list of common questions related to the Taxotere and the pending Taxotere lawsuits. What is Taxotere? Taxotere is an approved … [Read more...]
Zofran Lawsuit Frequently Asked Questions
By Desiree Housek, Staff Writer Zofran, an anti-nausea drug, has been shown to increase birth defects by 28-32% when taken during pregnancy. What is Zofran? Zofran (Ondansetron) belongs to the drug class known as antiemetic and selective 5-HT3 receptor antagonist. It is a medication that is prescribed to individuals for the treatment and … [Read more...]
Two Significant Developments Concerning Xarelto Litigation
Thousands of lawsuits have recently been filed by victims of the popular anti-blood clotting drug Xarelto, which can lead to uncontrollable bleeding in users due to its lack of a bleeding antidote. Marketed for its “once a day” dosage, the defective drug also poses risks to consumers when its effects wear off during the day or night, leaving … [Read more...]
Talcum Powder Lawsuit Frequently Asked Questions
By Desiree Housek, Staff Writer Johnson & Johnson’s baby powder and its Shower to Shower are two of the most popular products containing talcum powder, which has been linked to ovarian cancer. If you or a family member has been diagnosed with ovarian cancer after the use of talcum powder, here are some of the most commonly asked questions … [Read more...]
Zofran – Questions & Answers
By Victoria Ipri – Staff Writer Were you prescribed Zofran for nausea and vomiting while pregnant, then gave birth to a child with physical abnormalities? A January 2012 study from the Center for Birth Defects Research and Prevention reveals twice as many birth defects were caused by Zofran given during the first trimester, including cleft … [Read more...]
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 45
- Next Page »
Recent Comments